



10 February 2025

LungLife AI, Inc.
(the "Company" or "LungLife")

Change of Nominated Adviser and Joint Broker

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces the appointment of Allenby Capital Limited as the Company's Nominated Adviser and Joint Broker with immediate effect, alongside the Company's existing Joint broker, Goodbody.

AIM Rule 17 Schedule Two (g) information:

The Company also provides the following information relating to directors' disclosure under Rule 17 and Schedule Two, paragraph (g) of the AIM Rules for Companies:

LungLife's Chairman, Gordon Davis, was a director of C-Quantal Limited until his resignation on 28 February 2001. C-Quantal Limited entered into a creditors voluntary liquidation on 11 February 2002 and was subsequently dissolved on 18 August 2007.

For further information please contact:

LungLife AI, Inc.
Paul Pagano, CEO
David Anderson, CFO

www.lunglifeai.com
via investors@lunglifeai.com

Allenby Capital Limited
Nominated Adviser and Joint Broker
Alex Brearley / Lauren Wright - Corporate Finance
Matt Butlin / Guy McDougall - Equity Sales & Corporate Broking

Tel: +44 (0)20 3328 5656
info@allenbycapital.com

Goodbody
Joint Broker
Tom Nicholson / Cameron Duncan

Tel: +44 (0) 20 3841 6202

About LungLife

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com

Our Purpose is to be a driving force in the early detection to lung cancer. And our Vision is to invert the 20:80 ratio such that in years to come at least 80% of lung cancer is detected early.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

